RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - MECCANISMI CELLULARI E MOLECOLARI DEL RIMODELLAMENTO CARDIACO E NUOVE STRATEGIE TERAPEUTICHE.
• 2 - DIAGNOSTICA BIO-MOLECOLARE E TERAPIE INNOVATIVE NELL'INSUFFICIENZA CARDIACA.
• 3 - Genomica e proteomica del remodeling cardio-vascolare
• 4 - Meccanismi di segnalazione intracellulare responsabili della protezione dall'insufficienza cardiaca
• 5 - Meccanismi di danno e protezione nel miocardio ischemico
• 6 - EICOSANOIDI E MONOSSIDO DI AZOTO NEL DANNO ISCHEMICO CEREBRALE E NELLA RISOLUZIONE DELLA RISPOSTA INFIAMMATORIA AD ESSO ASSOCIATA
• 7 - RUOLO DEI MECCANISMI DI SEGNALE CELLULARE E DELLE SPECIE REATTIVE DELL'OSSIGENO E DELL'AZOTO NELL'INVECCHIAMENTO CELLULARE E NELLA CRESCITA NEOPLASTICA.
• 8 - EFFETTI DEGLI INIBITORI DELLA FOSFODIESTERASI TIPO 5 (PDE5i) SULLA FUNZIONE SESSUALE, ENDOCRINA E VASCOLARE
• 9 - Processi apoptotici nella differenziazione e degenerazione cellulare
• 10 - Basi molecolari della citotossicità indotta dai diversi stati di aggregazione di beta amiloide: studio multidisciplinare in vitro, su colture cellulari e su modello animale.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • GENETICA MEDICA
  • MEDICINA INTERNA
  • MALATTIE DELL'APPARATO CARDIOVASCOLARE
  • NEUROLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
• HUMAN NECESSITIES
  • AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

Classificazione geografica

• Regione: Lombardia

Bibliografia

1. Homcy CJ. Signaling hypertrophy. How many switches, how many wires. Circulation, 97: 1890-1892, 1998
2. McKinsey TA, Olson EN. Cardiac hyperthophy : sorting out the circuitry. Current Opinion in Genetics and Development, 9: 267-274, 1999
3. Molkentin JD, Dorn GW. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol, 63: 391-426, 2001
4. Marinissen MJ, Gutkind JS. G-protein coupled receptors and signaling networks:emerging paradigms. Trend Pharmacol Sci, 22:368-376, 2001
5. Nadal-Ginard B, Kaistura J, Leri A, Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res, 92: 139-150, 2003.
6. Hamet P, Richard L, Dam TV, Teiger E, Orlov SN, Gaboury L, Gossard F, Tremblay J. Apoptosis in target organs of hypertension. Hypertension. 1995;26:642-8.
7. Condorelli G, Morisco C, Stassi G, Notte A, Farina F, Sgaramella G, de Rienzo A, Roncarati R, Trimarco B, Lembo G. Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation. 1999;99:3071-8.
8. Cheng W, Li B, Kajstura J, Li P, Wolin MS, Sonnenblick EH, Hintze TH, Olivetti G, Anversa P. Stretch-induced programmed myocyte cell death. J Clin Invest. 1995;96:2247-59.
9. Webster KA, Bishopric NH. Apoptosis inhibithors for heart disease. Circulation, 108:2954-2956, 2003.
10. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, et al. Enhanced G q signaling: A common pathway mediates cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. USA 95:10140–45, 1998.
11. Knowlton KU, Michel MC, Itani M, Schubeita HE, Ishihara K, et al. The alpha1-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J. Biol. Chem. 268:15374–80, 1993.
12.Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. USA 96:7059–64, 1999
13. Ichihara S, Senbonmatsu T, Price E et al. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation, 104:346-351, 2001
14. Schneider MD, Lorell BH. AT2, Judgement Day. Which angiotensin receptor is the culprit in cardiac hypertrophy? Circulation, 104: 247-248, 2001.
15. LaMorte VJ, Thorburn J, Absher D, Spiegel A, Brown JH, et al. Gq- and/Ras-dependent pathways mediate hypertrophy of neonatal rat ventricular myocytes following alpha1-adrenergic stimulation. J. Biol. Chem. 269:13490–96, 1994.
16. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, Neer EJ. Transient cardiac expression of constitutively active G q leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc. Natl. Acad. Sci. USA 95:13893–98, 1998.
17. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280: 574–77, 1998.
18. MacLellan WR, Schneider MD. Genetic dissection of cardiac growth control pathways. Annu Rev Physiol, 62: 289-319, 2000.
19. Yamamoto S, Yang G, Zablocki D, Liu J, Hong C, Kim SJ, Soler S, Odashima M, Thaisz J, Yehia G, Molina CA, Yatani A, Vatner DE, Vatner SF, Sadoshima J. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocytes hypertrophy. J Clin Invest 2003;111:1463-1474
20. Cook SA, Sugden PH, Clerk A. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol 1999;31:1429-1434.
21. Clerk A, M.A., Sugden PH. (1998). Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J Cell Biol, 142, 523-35.
22. De Windt LJ, L.H., Bueno OF, Liang Q, Delling U, Braz JC, Glascock BJ, Kimball TF, del Monte F, Hajjar RJ, Molkentin JD. (2001). Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A., 98, 3322-3327.
23. Eto Y, Y.K., Sonoda M, Arai N, Sata M, Sugiura S, Takenaka K, Gualberto A, Hixon ML, Wagner MW, Aoyagi T. (2000). Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training. Circulation, 101, 2134-2137.
24. Hayashida W, K.Y., Yasaka A, Sasayama S. (2000). Cardiac calcineurin during transition from hypertrophy to heart failure in rats. Biochem Biophys Res Commun, 273, 347-51.
25. Molkentin JD, L.J., Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. (1998). A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell, 93, 215-228.
26. Ritter O, H.S., Schuh K, Rothlein N, Perrot A, Osterziel KJ, Schulte HD, Neyses L. (2002). Calcineurin in human heart hypertrophy. Circulation, 105, 2265-9.
27. Taigen T, D.W.L., Lim HW, Molkentin JD. (2000). Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A., 97, 1196-1201.
28. Wilkins BJ, D.Y., Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD. (2004). Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res, 94, 110-118.
29. Rigaud AS, Seux ML, Staessen JA, Birkenhager WH, Forette F. Cerebral complications of hypertension. J Hum Hypertens 2000;14:605-16
30. Zalba G, San Jose G, Moreno MU, Fortuno MA, Fortuno A, Beaumont FJ, Diez J. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension. 2001 Dec 1;38(6):1395-9
31. Kumar D, Jugdutt BI. Apoptosis and oxidants in the heart. J Lab Clin Med, 142.288-297, 2003.

Parole Chiave

IPERTENSIONE ARTERIOSA; DANNO D'ORGANO; IPERTROFIA CARDIOVASCOLARE; SCOMPENSO CARDIACO; APOPTOSI; STRESS OSSIDATIVO; POLIMORFISMO GENETICO; ESPRESSIONE GENICA; PROTEOMICA